Phospholipase D Activation by v-Src and v-Ras: In response to the oncogenic stimuli of v-Src, there is an activation of phospholipase D (PLD) that is dependent upon a GTPase cascade of Ras and Ral. Transformation by v-Src is also dependent upon both Ras and Ral, suggesting a role for PLD in cell transformation. PLD hydrolyzes phosphatidylcholine to phosphatidic acid (PA) and choline. The best understood effects of PA are mediated by the PA metabolite diacylglycerol, which leads to the activation of protein kinase C. However, PA is also biologically active and has been implicated in regulating a variety of signaling molecules including Raf-l, phosphatidylinositol kinases, and the GTPase activating proteins (GAPs) for Ras, Rac and Arf. PLD activity and PA have also been implicated in vesicle transport. Although RalA is required for v-Src-induced PLD activity and PLD exists in a complex with Ral, an activated RalA is not sufficient for PLD activation. Biochemical and genetic evidence suggest at least two factors in addition to RalA are required for PLD activation by v-Src. The objective of the proposed studies is to characterize the interaction between RalA and PLD and to identify factors contributing to the activation of PLD via the newly emerging Ras/Ral signaling pathway. Candidate proteins implicated in the activation of PLD by v-Src are the Rho family GTPases Rho, Rac, Cdc42 and the RalA binding protein Ral-BP1, which is a GAP protein for Rho family GTPases. Arf (ADP ribosylation factor), which activates the PLD associated with RalA is another candidate. Proposed studies will test whether these and other implicated factors contribute to activation of PLD by v-Src. Because of the many extracellular stimuli that activate PLD via tyrosine kinases and the many intracellular responses to the PLD-generated PA, understanding of the mechanism of PLD activation by tyrosine kinases will provide several new targets for therapeutic intervention in diseases such as human breast cancer where altered regulation of tyrosine kinase activity has been implicated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA046677-06A4
Application #
2007691
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1989-08-25
Project End
2000-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Hunter College
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10065
Utter, Matthew; Chakraborty, Sohag; Goren, Limor et al. (2018) Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes. Cancer Lett 423:28-35
Bernfeld, Elyssa; Menon, Deepak; Vaghela, Vishaldeep et al. (2018) Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine. J Biol Chem 293:16390-16401
Patel, Deven; Salloum, Darin; Saqcena, Mahesh et al. (2017) A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells. J Biol Chem 292:936-944
Menon, Deepak; Salloum, Darin; Bernfeld, Elyssa et al. (2017) Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid. J Biol Chem 292:6303-6311
Patel, Deven; Menon, Deepak; Bernfeld, Elyssa et al. (2016) Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells. J Biol Chem 291:9322-9
Mukhopadhyay, Suman; Frias, Maria A; Chatterjee, Amrita et al. (2016) The Enigma of Rapamycin Dosage. Mol Cancer Ther 15:347-53
Saqcena, M; Mukhopadhyay, S; Hosny, C et al. (2015) Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 34:2672-80
Saqcena, Mahesh; Patel, Deven; Menon, Deepak et al. (2015) Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. Cell Cycle 14:2285-92
Mukhopadhyay, Suman; Chatterjee, Amrita; Kogan, Diane et al. (2015) 5-Aminoimidazole-4-carboxamide-1-?-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle 14:3331-9
LeGendre, Onica; Breslin, Paul As; Foster, David A (2015) (-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. Mol Cell Oncol 2:e1006077

Showing the most recent 10 out of 33 publications